Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MADRIGAL PHARMACEUTICALS, INC. via MADRIGAL PHARMACEUTICALS, INC.
2026 · third_quarter · Q3
Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Issues related to CMMI drug pricing; 340B drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
2026 · second_quarter · Q2
Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Issues related to CMMI drug pricing; 340B drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MADRIGAL PHARMACEUTICALS, INC. via MADRIGAL PHARMACEUTICALS, INC.
2026 · first_quarter · Q1
Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Issues related to CMMI drug pricing; 340B drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MADRIGAL PHARMACEUTICALS, INC. via MADRIGAL PHARMACEUTICALS, INC.
2025 · fourth_quarter · Q4
Issues related to CMMI drug pricing
Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MADRIGAL PHARMACEUTICALS, INC. via MADRIGAL PHARMACEUTICALS, INC.
2025 · third_quarter · 3A
Most Favored Nation drug pricing
MADRIGAL PHARMACEUTICALS, INC. via MADRIGAL PHARMACEUTICALS, INC.
2025 · third_quarter · RR
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry
FDA and regulatory issues related to the biopharmaceutical industry